Prognostic impact of ATM mutations in patients with metastatic colorectal cancer by G. Randon et al.
1Scientific RepoRts |          (2019) 9:2858  | https://doi.org/10.1038/s41598-019-39525-3
www.nature.com/scientificreports
prognostic impact of ATM 
mutations in patients with 
metastatic colorectal cancer
Giovanni Randon1, Giovanni Fucà  1, Daniele Rossini2, Alessandra Raimondi1, 
Filippo pagani1, Federica perrone3, elena tamborini3, Adele Busico  3, Giorgia peverelli1, 
Federica Morano1, Monica Niger1, Maria Antista1, salvatore Corallo  1, serena saggio1, 
Beatrice Borelli2, Gemma Zucchelli2, Massimo Milione3, Giancarlo pruneri3,4, 
Maria Di Bartolomeo1, Alfredo Falcone2,5, Filippo de Braud1,4, Chiara Cremolini2,5 & 
Filippo pietrantonio1,4
Tumors bearing homologous recombination deficiency are extremely sensitive to DNA double strand 
breaks induced by several chemotherapeutic agents. ATM gene, encoding a protein involved in DNA 
damage response, is frequently mutated in colorectal cancer (CRC), but its potential role as predictive 
and prognostic biomarker has not been fully investigated. We carried out a multicenter effort aimed 
at defining the prognostic impact of ATM mutational status in metastatic CRC (mCRC) patients. 
Mutational profiles were obtained by means of next-generation sequencing. Overall, 35 out of 227 
samples (15%) carried an ATM mutation. At a median follow-up of 56.6 months, patients with ATM 
mutated tumors showed a significantly longer median overall survival (OS) versus ATM wild-type ones 
(64.9 vs 34.8 months; HR, 0.50; 95% CI, 0.29–0.85; P = 0.01). In the multivariable model, ATM mutations 
confirmed the association with longer OS (HR, 0.57; 95% CI, 0.33–0.98; P = 0.04). The prognostic impact 
of ATM mutations was independent from TP53 mutational status and primary tumor location. High 
heterogeneity score for ATM mutations, possibly reflecting the loss of wild-type allele, was associated 
with excellent prognosis. In conclusion, we showed that ATM mutations are independently associated 
with longer OS in patients with mCRC.
Significant advances in the implementation of biomarkers in the clinical practice have been achieved in metastatic 
colorectal cancer (mCRC), even if only few of them (such as RAS and BRAF mutational status or microsatellite 
instability [MSI]) are endowed with clinical relevance. Furthermore, despite the advances achieved in under-
standing the molecular bases of resistance to EGFR targeting agents1–3, there is still a lack of biomarkers able to 
predict sensitivity/resistance to chemotherapy, which remains the cornerstone of treatment for most patients.
Cancer cells may gain the potential for uncontrolled growth by escaping functional cell-cycle checkpoints. By 
doing so, they simultaneously become vulnerable to both endogenous (e.g. oncogenic-driven replication stress) 
and exogenous (e.g. DNA-damaging agents) genotoxic insults4. Tumors with homologous recombination defi-
ciency are extremely sensitive to cross-linking agents such as platinum salts, or topoisomerase inhibitors. This 
mechanism has substantial implications in the clinical practice, specifically concerning the management of those 
tumors bearing deleterious BRCA1-2 mutations (e.g. BRCA-mutated breast and ovarian cancer)5,6.
Ataxia-Telangiectasia Mutated (ATM) is a gene member of the highly conserved PI3K-related kinases, on 
which cells rely for orchestrating the DNA damage response (DDR) for both DNA repair and cell-cycle check-
point activation. Specifically, ATM is recruited upon DNA double strand breaks (DSBs) and is involved in DNA 
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repair via both BRCA1-driven homologous recombination and non-homologous end-joining pathways, as well 
as in the G1/S cellular checkpoint activation through its major targets p53 and CHK27.
Germline and somatic mutations involving homologous recombination related genes, including ATM, are 
predicted to confer an enhanced platinum sensitivity8. Specifically, ATM deficient tumors display a higher sen-
sitivity to DNA DSB-inducing treatments9 and loss of function mutations affecting the ATM gene could confer a 
vulnerability to DNA-damaging agents, especially in combination with p53 deficiency10–13. Because of the con-
sistent prevalence of ATM mutations in CRC (7% in non-hypermutated cases)14 and their potential crucial role as 
biomarker of chemosensitivity to platinum salts and topoisomerase inhibitors, ATM mutations would therefore 
characterize mCRC patients with a more favourable outcome, at least when eligible for combination chemo-
therapy. Moving from this background, we performed a translational study aimed at assessing the prognostic 
relevance of ATM mutational status in mCRC patients.
Materials and Methods
Patients population. We retrieved pre-treatment tumor tissue blocks of initially unresectable mCRC 
patients treated at two Italian Institutions (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and 
Azienda Ospedaliero-Universitaria Pisana). Clinical, pathological and molecular characteristics at the time of 
diagnosis of metastatic disease were collected, including age, gender, Eastern Cooperative Oncology Group 
(ECOG) Performance Status (PS), primary tumor location (right- vs left-sided), primary tumor resection (yes vs 
no), time-to-metastases (synchronous vs metachronous), number of metastatic sites (1 vs >1), RAS and BRAF 
mutational status, and MSI status. All included patients received at least one treatment line with doublet or triplet 
regimens with or without monoclonal antibodies according to standard clinical practice. The study was approved 
by the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Institutional Review Board (study ID: INT 
117/15) and conducted according to the ethical principles for medical research involving human subjects adopted 
in the Declaration of Helsinki. All patients signed a written informed consent.
Next-generation sequencing analysis. We centrally collected formalin-fixed paraffin-embedded archi-
val tumor tissue blocks. Next-generation sequencing (NGS) data were obtained through the Ion AmpliSeq 
Cancer Hotspot Panel v2 (Life Technologies) with the Ion-Torrent™ Personal Genome Machine platform 
(Life Technologies), as previously described15,16 and detailed in Supplementary Methods (see Supplementary 
Information). ATM and TP53 mutational status was obtained, and RAS and BRAF mutational status was centrally 
confirmed. Heterogeneity score (HS) of ATM mutations was calculated as previously described by Normanno 
et al.17. Briefly, the mutant allelic frequency was normalized for the neoplastic cell content, and the HS was calcu-
lated by multiplying by 2 the frequency of mutant alleles in neoplastic cells as somatic mutations usually involve 
only one allele.
Statistical analysis. Chi-square test or fisher exact test were used, as appropriate, to evaluate the association 
between ATM mutational status and the other relevant clinical and pathological patients’ characteristics. Overall 
survival (OS) was calculated as the time from diagnosis of metastatic disease to the death from any cause. Since 
chemotherapy sensitivity putatively caused by ATM mutations may be boosted by the concomitant presence of 
Characteristics
Total
(N = 227)
N (%)
ATM mut
(N = 35)
N (%)
ATM wt
(N = 192)
N (%) P*
Age (years) <65≥65
147 (65)
80 (35)
25 (71)
10 (29)
122 (64)
70 (36) 0.40
Gender MaleFemale
93 (41)
134 (59)
17 (49)
18 (51)
76 (40)
116 (60) 0.32
ECOG PS
0
1–2
NA
197 (92)
18 (8)
12
34 (97)
1(3)
0
163 (91)
17 (9)
12
0.20
Primary tumor location Left-sidedRight-sided
159 (70)
68 (30)
27 (77)
8 (23)
132 (69)
60 (31) 0.32
Primary tumor 
resection
Yes
No
192 (85)
35 (15)
31 (89)
4 (11)
161 (84)
31 (16) 0.48
Synchronous mets NoYes
67 (30)
160 (70)
13 (37)
22 (63)
54 (28)
138 (72) 0.28
Metastatic sites (N) 1>1
135 (59)
92 (41)
24 (69)
11 (31)
111 (58)
81 (42) 0.23
All-RAS status Wild-typeMutated
127 (56)
100 (44)
20 (57)
15 (43)
107 (56)
85 (44) 0.88
BRAF status Wild-typeMutated
214 (94)
13 (6)
33 (94)
2 (6)
181 (94)
11 (6) 0.99
MSI status
MSS
MSI
NA
188 (94)
13 (6)
26
26 (87)
4 (13)
5
162 (95)
9 (5)
21
0.11
Table 1. Patients’ and disease characteristics, overall and according to ATM mutational status. *Chi-square 
test or Fisher exact test, as appropriate. Abbreviations. ECOG PS: Eastern Cooperative Oncology Group 
Performance Status. MSI: microsatellite instability. MSS: microsatellite stability. Mut: mutated. Wt: wild-type.
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TP53 mutations10 or primary tumor sidedness due to enrichment of mesenchymal and stem-like subtypes in 
right-sided tumors18 we also evaluated the prognostic impact of combined ATM and TP53 mutational status 
assessment as well as the prognostic impact of combined ATM mutational status and primary tumor location. The 
Kaplan-Meier method and the Cox proportional-hazards model were used for survival analyses. Hazard ratios 
(HRs) together with 95% confidence intervals (CI) were provided. Statistical significance threshold was set to a 
two-tailed 0.05 value. R software (version 3.5.0) and RStudio software (version 1.1.453) were used for Statistical 
analyses.
Results
Clinical, pathological and molecular features of ATM mutated mCRC. As detailed in the Consort 
diagram (Supplementary Fig. S1 in Supplementary Information), the final study population included a total of 
227 patients, of whom 35 (15%) had ATM mutated tumors and 192 (85%) ATM wild-type tumors. TP53 muta-
tions were found in a total of 148 (65%) of samples, of whom 24 (69%) in the ATM mutated subgroup and 124 
(65%) in ATM wild-type one (P = 0.65). Table 1 shows patients’ demographics and disease characteristics, overall 
and according to ATM mutational status. Of note, ATM mutations were not significantly associated with specific 
clinical and molecular features. The exposure to specific agents approved for mCRC and the number of treatment 
lines received are summarized in Supplementary Table S1 (see Supplementary Information). Table 2 illustrates the 
ID
MSI 
status
ATM TP53 KRAS NRAS BRAF APC
Mutation HS Mutation HS Mutation HS Mutation HS Mutation HS Mutation HS
1 MSI K610T 60 R248Q 70 G12V 70 — — — — E1464VfsTer8 44
2 NA E1325Stop 94 R175C 180 — — — — — — — —
3 MSS D2870H 52 — — G12S 114 — — — — R1450Stop 106
4 MSS R3047Stop 88 — — G12D 58 — — — — R1450Stop 46
5 MSI R337C 32 — — G13D 36 — — — — I1307K 156
6 MSS P3050L 254 P278S 173 Q61H 120 — — — — — —
7 MSI P604S 132 R196Stop 194 G12V 140 — — — — E1286Stop 198
8 MSS R337C 30 I254S 200 G12V 140 — — — — R1450Stop 64
9 MSS A1309T 136 S215R 192 — — — — — — S1346Stop 72
10 MSS V410A 230 — — — — — — — — — —
11 MSS R337H 34 — — — — — — — I1311MfsTer10 200
12 NA R2443Q 184 R273C 290 — — — — — — E1353FfsTer20 284
13 MSS R337C 114 — — A146T 212 — — — — T1438HfsTer35 106
14 MSS E1704D 240 — — — — — — — — E1379Stop 710
15 MSS Q2729H 128 — — A146T 104 — — — — T1556NfsTer3 76
16 MSS V410A 200 — — — — — — — — E1309DfsTer4 158
17 MSS R337H 46 R249G 42 G12V 46 — — — — — —
18 MSS P604S 194 R273H 306 — — — — — — Q12894Stop 320
19 MSS R2691H 52 C238Y 122 — — — — — — E1317Q 158
20 MSS R337C 50 — — G12V 96 — — — — H1349QfsTer4 166
21 MSS S333F 40 G266E 760 — — — — — — — —
22 MSS L1939V 44 R282W 268 — — — — — — — —
23 MSS V410A 142 I251S 98 — — — — — — E1547Stop 86
24 MSS V410A 314 Y205H 207 — — — — — — — —
25 MSS R337H 108 R175H 196 G13D 190 — — — — — —
26 MSS S333F 290 R273C 140 — — — — — — — —
27 MSS S1691R 204 R175H 113 — — — — — — — —
28 MSS splice site 184_185 + K1992T 212 + 102 V73fs*50 90 — — — — V600E 350 — —
29 MSI F1928fs*9 206 R27H + R17H 340 — — — — V600E 468 — —
30 MSS F858L 300 V274F 66 — — — — — — — —
31 MSS R337H 20 — — A146T 140 — — — — — —
32 MSS R2912G 116 R2912G 400 — — G12S 120 — — — —
33 MSS G2695V 46 G245S 60 — — — — — — R1450Stop 50
34 MSS V410A 132 R273C 108 G12V — — — — — R1450Stop 62
35 MSS F858L 146 R282W 202 — — — — — — Q1291Stop 84
Table 2. Specific mutations found in ATM gene with concomitant “trunk” mutations (affecting TP53, KRAS, 
NRAS, BRAF and APC) with relative heterogeneity score. Abbreviations. HS: heterogeneity score. MSI: 
microsatellite instability. MSS: microsatellite stability.
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specific mutations found in ATM gene and concomitant “trunk” mutations affecting TP53, KRAS, NRAS, BRAF 
and APC, with relative HS. The median HS for ATM mutations was 116 (IQR, 51–197).
Prognostic role of ATM mutations in mCRC patients. At a median follow-up of 56.6 months (95% CI, 
46.3–62.1), patients with ATM mutated tumors showed a significantly longer median OS than patients with ATM 
wild-type tumors (64.9 versus 34.8 months; HR, 0.50; 95% CI, 0.29–0.85; P = 0.01) (Fig. 1). In the multivariable 
model (Table 3), including other covariates significantly associated with OS, the presence of ATM mutations con-
firmed its association with improved OS (HR, 0.57; 95% CI, 0.33–0.98; P = 0.04), along with left-sided primary 
tumor location (P = 0.005), primary tumor resection (P = 0.003), metachronous metastases (P = 0.005) and the 
presence of a single site of metastasis (P = 0.03).
Among patients with ATM mutated tumors, an HS ≥ 100 for ATM mutations was associated with a longer 
median OS compared with an HS < 100 (70.1 versus 38.5 months; HR, 0.28; 95% CI 0.09–0.85; P = 0.02) (Fig. 2). 
Therefore, when using patients with wild-type ATM as reference, the HR for patients with ATM mutated tumors 
and HS < 100 was 0.91 (95% CI, 0.44–1.86; P = 0.79), whereas it relevantly decreased for patients with ATM 
mutated tumors and HS ≥ 100 (HR, 0.57; 95% CI, 0.39–0.84; P = 0.004).
Of note, no prognostic significance was observed for TP53 mutational status (P = 0.79), and the prognos-
tic impact of ATM mutations was completely independent from the concomitant presence of TP53 mutations 
(Supplementary Fig. S2 in Supplementary Information) or primary tumor sidedness (Supplementary Fig. S3 in 
Supplementary Information).
Finally, since we performed a massively parallel sequencing of multiple cancer-related genes, we assessed the 
prognostic value of the top mutated genes (i.e. those found mutated in at least 5% of samples: ATM, KRAS, BRAF, 
NRAS, APC, PIK3CA, SMAD4, FBXW7 and MET) and applied the Benjamini–Hochberg procedure in order to 
decrease the false discovery rate, demonstrating that the P-value for ATM mutational status remained significant 
(P = 0.04) (Supplementary Table S2 in Supplementary Information).
Discussion
Given the crucial role of ATM activity in orchestrating the DDR, relevant phenotypic spillover is awaited upon 
its loss. However, as a result of both biological complexity of the DDR network and heterogeneity across different 
studies, no conclusive clinical data are available on ATM prognostic and/or predictive impact.
In early stage CRC, low ATM expression has been previously associated with worse outcomes. In a series of 
330 early CRCs, the presence of ATM expression detected by immunohistochemistry (IHC) was associated with 
disease-free survival and OS benefit when considering patients who underwent adjuvant treatments (N = 33)19. 
Similar results have been confirmed by a subgroup analysis of the VICTOR trial, which included stage II/III CRC 
patients undergoing adjuvant fluoropyrimidine-based chemotherapy20. Regarding the metastatic setting, a recent 
monocentric study showed that ATM deficiency (as primarily assessed by IHC) may be associated with improved 
OS following oxaliplatin-based first-line treatment, but not irinotecan-based one21. Discrepancy in available evi-
dences might be related to the different prognostic role of ATM loss of function according to disease stage, simi-
larly to what reported for MSI22, and the confounding effects derived from the heterogeneity of available regimens 
and treatment sequences used for metastatic disease.
Figure 1. Kaplan-Meier curves for overall survival according to ATM mutational status. Red line indicates 
patients with ATM mutated tumors, blue line indicates patients with ATM wild-type tumors.
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This is the larger available study assessing the role of ATM mutations as prognostic biomarker in mCRC. Here, 
the presence of ATM mutations was independently associated with improved OS (adjusted HR, 0.57; 95% CI, 
0.33–0.98; P = 0.04). These results suggest that ATM mutations might identify a biologically distinct disease with a 
survival advantage in the metastatic setting linked, at least in part, to an increased chemosensitivity. Intriguingly, 
patients with ATM mutations and an HS ≥ 100, showed the best outcomes in terms of OS. As previously described 
by Normanno et al.17, HS virtually corresponds to the fraction of neoplastic cells bearing a specific mutation. 
Specifically, an HS > 100 might reflect the loss of the wild-type allele. HS might help identifying tumors with a 
“functional knock-out” of ATM that lose their ability of properly coping with DNA damage. Therefore ATM HS 
should be taken into account by future studies and potentially correlated with functional data.
From a preclinical point of view, p53 is one of the most characterized ATM targets, required for G1/S cell arrest 
and apoptosis. Conceptually, drugs inducing high amount of DNA damage in S phase in cells with both DNA repair 
and G1/S–G2/M checkpoint deficiency (such as those bearing both ATM and TP53 mutations) are likely to induce 
a mitotic catastrophe-mediated cell death23. However, we did not find any clinically relevant interaction between 
ATM and TP53 mutational status in impacting on OS (Supplementary Fig. S2 in Supplementary Information). It 
must be pointed out that, even if ATM or CHK2 suppression preferentially sensitizes p53 deficient tumors to geno-
toxic drugs, a chemosensitivity status driven by ATM deficiency might occur independently from TP5324.
In addition, an enrichment of ATM mutations is expected in mCRC patients with right-sided tumors18, 
MSI-high14 or CMS1 ones25. In our study, the prognostic impact of ATM mutational status was independent from 
Characteristics
Univariate analyses Multivariable model
HR (95% CI) P HR (95% CI) P
Age (years) ≥65 vs <65 1.60 (1.10–2.20) 0.009 — 0.25
Gender Female vs Male — 0.24 — —
ECOG PS 1–2 vs 0 — 0.15 — —
Primary tumor location Right vs Left 2.00 (1.40–2.80) <0.001 1.70 (1.17–2.46) 0.005
Primary tumor resection No vs Yes 1.90 (1.20–2.90) 0.005 1.62 (1.04–2.54) 0.03
Synchronous mets Yes vs No 1.80 (1.20–2.60) 0.003 1.76 (1.19–2.61) 0.005
Metastatic sites (N) >1 vs 1 1.70 (1.20–2.40) 0.002 1.47 (1.03–2.08) 0.03
All-RAS status Mut vs wt — 0.06 — —
BRAF status Mut vs wt 2.10 (1.10–4.00) 0.03 — 0.09
MSI status MSI vs MSS — 0.16 — —
ATM status Mut vs wt 0.50 (0.29–0.85) 0.01 0.57 (0.33–0.98) 0.04
Table 3. Univariate and multivariate analyses for overall survival. Abbreviations. ECOG PS: Eastern 
Cooperative Oncology Group Performance Status. Mets: metastases. MSI: microsatellite instability. MSS: 
microsatellite stable. Mut: mutated. Wt: wild-type.
Figure 2. Kaplan-Meier curves for overall survival according to ATM mutational status and ATM mutational 
heterogeneity score. Red line indicates patients with ATM mutated tumors and ATM HS ≥ 100, blue line 
indicates patients with ATM mutated tumors and ATM HS < 100, black line indicated patients with ATM wild-
type tumors. Abbreviations: HS: heterogeneity score.
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primary tumor location status (Table 3 and Supplementary Fig. S3 in Supplementary Information), even if the low 
number of patients with ATM mutations and right-sided mCRC highlights the need of larger datasets to specifi-
cally assess the impact of DDR alterations according to primary tumor location or disease subtypes.
Our study has some limitations. For instance, despite the strong rationale making ATM mutational sta-
tus a candidate biomarker of response to oxaliplatin and/or irinotecan26–29, we have not considered response 
rate or progression-free survival because of the heterogeneity of treatment regimens as per standard practice 
(fluoropyrimidine monotherapy, doublet or triplet chemotherapy regimens associated or not with anti-VEGF or 
anti-EGFR). Of course, an integrated assessment of both protein expression and mutational status would be nec-
essary for identifying all tumors with clinically relevant ATM loss of function. In fact, other mechanisms might 
account for ATM reduced activity, such as low expression due to promoter methylation30. Indeed, a comprehen-
sive assessment of the DDR network on a proteomic scale is expected to reach the best accuracy for predicting 
chemosensitivity.
Beyond being a sole biomarker of chemosensitivity, ATM mutations might predict response to DDR-targeting 
agents paralleling recent achievements in other clinical settings, such as castration-resistant prostate cancer 
(CRPC). Indeed, in the TOPARP-A phase II trial CRPC patients bearing alterations in homologous recombi-
nation repair genes displayed a high response rate to the PARP inhibitor olaparib (including 4 out of 5 patients 
with tumors bearing ATM mutations)31. Similar therapeutic approach would be backed by a strong preclinical 
rationale also in CRC32. The reader is referred to Choi et al.33 for reviewing potential synthetic lethality strategies 
(e.g PARP1 or ATR inhibitors) in ATM deficient tumors.
In conclusion, our study suggests that ATM mutations with high HS might characterize a subset of mCRC 
at better prognosis. From this background, further investigations are needed to cover crucial unresolved issues 
such as the assessment of functional relevance of specific ATM mutations and their predictive role upon specific 
DNA damaging and/or DDR-targeting agents. Indeed, synthetic lethality strategies might be preferentially used 
in ATM deficient tumors, while ATM proficient tumors might be sensitized to conventional therapies by ATM 
inhibitors34. Thus, ATM mutational status could enter the clinical decision-taking process in parallel with the 
development of specific targeted strategies.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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